1. Introduction {#sec1}
===============

Arsenic trioxide (As~2~O~3~), an old drug well-known for its rediscovery in the treatment of acute promyelocytic leukemia (APL)[@bib1], was shown to have therapeutic potential in a number of mouse models of autoimmune disorders including systemic sclerosis (SSc)[@bib2]^,^[@bib3], with largely unknown mechanism. Apoptosis induction and NF-*κ*B pathway inhibition are two mechanisms generally known for As~2~O~3~ efficacy, but are not disease-specific[@bib4]^,^[@bib5].

Plasmacytoid dendritic cells (pDCs) are a unique subset of dendritic cells specialized in secreting high levels of type-I interferons (IFN-I), and are lately identified to play crucial pathogenetic role in SSc[@bib6]. Thus, in a SSc mouse model with bleomycin-induced fibrosis, depletion of pDCs not only prevented the disease initiation, but ameliorated the established fibrosis[@bib7]^,^[@bib8]. Furthermore, in human, abnormally activated pDCs are infiltrated in the target organs such as skin, lung and bronchoalveolar lavage, and secrete IFN-*α* and CXCL4, which are both hallmarks of SSc[@bib8]^,^[@bib9].

Abnormal T and B cell responses are both key factors in the pathogenesis of SSc[@bib10], [@bib11], [@bib12]. Upon activation by different signals, pDCs mature and present antigen to CD4^+^ T cells, leading to Th1, Th2, Th17 or Treg responses[@bib13], [@bib14], [@bib15]. On the other hand, IFN-*α* and IL-6 secreted by pDCs, as well as cell-to-cell contacts mediate the differentiation of B cells into plasmablasts and immunoglobulin-secreting plasma cells[@bib16], [@bib17], [@bib18]. Overall, pDCs appear to be a promising therapeutic target in SSc treatment.

We conducted experiments to look into how As~2~O~3~ affects pDCs from both healthy donors and SSc patients, and to investigate the underlying mechanisms.

2. Materials and methods {#sec2}
========================

2.1. Media and reagents {#sec2.1}
-----------------------

Complete medium was RPMI-1640 supplemented with 1 mmol/L sodium pyruvate, 2 mmol/L [l]{.smallcaps}-glutamine, MEM vitamin solutions, 100 U/mL penicillin, 100 μg/mL streptomycin and 10% heat-inactivated fetal bovine serum (all from Thermo Fisher Scientific, Villebon-sur-Yvette, France). CpG oligodeoxyribonucleotides (ODNs) are toll-like receptor 9 (TLR9) agonists. 1.5 μmol/L of class A CpG ODN 2216 (CpG-A), 1.5 μmol/L of class B CpG ODN 2006 (CpG-B), or 1 μmol/L of class P CpG ODN 21798 (CpG-P) (all from Miltenyi Biotec, Paris, France) were used to activate pDCs *in vitro* in this study. CpG-A is a strong inducer of type I IFNs, whereas CpG-B is a potent stimulator of maturation and the production of cytokines and chemokines. CpG-P exhibits properties of both CpG-A and CpG-B. The stock solution of As~2~O~3~ (6672 μmol/L) was reconstituted by dissolving As~2~O~3~ (Sigma--Aldrich, Saint-Quentin Fallavier, France) powder into distilled water and stored in 4 °C fridge. The solution was then diluted in complete medium to reach the target concentrations. For control condition a similar volume of complete medium was added.

2.2. pDC isolation and culture {#sec2.2}
------------------------------

Peripheral blood mononuclear cells (PBMCs) were obtained from buffy coats by Ficoll density centrifugation, from healthy donors (Etablissement Français du Sang, Paris Saint-Antoine-Crozatier, France) or untreated SSc patients (Hôpital Saint-Antoine, Paris, France) after informed consent. The study was approved by the local institutional review board and the Comité de Protection des Personnes Ile-de France VII (CPP Ouest-1, reference 2017-A03380-53). pDCs were negatively selected with EasySep™ Human Plasmacytoid DC Enrichment Kit (Stem cell, Grenoble, France). The purity of isolated pDCs, verified by flow cytometry using PE-Vio770-BDCA2 (Miltenyi Biotec), ECD-CD123 (Beckman Coulter, Villepinte, France), was \>90%.

2.3. pDC viability and apoptosis {#sec2.3}
--------------------------------

Isolated pDCs were cultured in the presence of 10 ng/mL IL-3 (Miltenyi Biotec), or activated with CpG-A/CpG-P in the presence of the indicated doses of As~2~O~3~. Viability and apoptosis were checked with Fixable Viability Dye eFluor™ 506 (FVD, Thermo Fisher Scientific) and FITC Annexin V (Biolegend, Ozyme, Saint-Quentin-Fallavier, France). FVD^--^Annexin V^--^ cells were regarded as viable, FVD^+^ cells as dead, and FVD^--^Annexin V^+^ cells as apoptotic. For NAC (Sigma--Aldrich) treatment, pDCs were pre-treated with 1 mmol/L of NAC for 1 h, washed and placed in culture for 6 h. For BCL-2 and BAX staining, isolated pDCs were cultured for 6 h in complete culture medium in the presence of 10 ng/mL IL-3, or activated with CpG-A in the presence of 5 μmol/L As~2~O~3.~ Afterwards cells were stained with PE-BCL-2 (BD Biosciences, Le Pont de Claix, France) and Alexa Fluor® 488-BAX (Biolegend, Ozyme) or the corresponding isotype controls, using the FOXP3/Transcription Factor Staining Buffer Set (Thermo Fisher Scientific).

2.4. Reactive oxygen species {#sec2.4}
----------------------------

Isolated pDCs were cultured for 30 min in complete medium in the presence of 10 ng/mL IL-3, with or without activation with CpG-A and 5 μmol/L As~2~O~3~. Instead of As~2~O~3~, pDCs were cultured simultaneously with 200 μmol/L of *tert*-butyl hydroperoxide as positive control. For negative control, pDCs were pre-treated with 1 mmol/L of antioxidant *N*-acetylcysteine (NAC) for 1 h. Reactive oxygen species (ROS) level was detected with CellROX® Green Flow Cytometry Assay Kits (Thermo Fisher Scientific).

2.5. Cytokine secretion analysis {#sec2.5}
--------------------------------

PBMCs were incubated with increasing doses of As~2~O~3~, activated with CpG-A for 6 h, and 1 μL/mL Golgi plug (BD Biosciences) was added in the last 3 h. The cells were firstly stained with FVD eFluor™ 506, then with PE-Vio770-BDCA2 (Miltenyi Biotec) and ECD-CD123 (Beckman Coulter). Cells were then stained with FITC-IFN-*α* and APC-Vio770-TNF-*α* (both from Miltenyi Biotec) with Cytofix/Cytoperm Buffer (BD Biosciences).

2.6. Cell signaling staining {#sec2.6}
----------------------------

Isolated pDCs were cultured overnight in the absence of IL-3, with or without CpG-A and 1 μmol/L of As~2~O~3~. Afterwards, the cells were fixed with Cytofix™ Fixation Buffer (BD Biosciences), permeabilized with Phosflow™ Perm Buffer III (BD Biosciences), and then stained with APC-interferon regulatory factor 7 (IRF7) and PE-IRF7 pS477/pS479 (both from Miltenyi Biotec).

2.7. Gene expression analysis {#sec2.7}
-----------------------------

Isolated pDCs were cultured for 6 h in the absence of IL-3, with or without CpG-A and 1 μmol/L of As~2~O~3~. RNA was then extracted using RNAeasy Mini kit (QIAGEN, Les Ulis, France). RNA was subjected to reverse transcription (High Capacity RNA-to-cDNA Master Mix, Thermo Fisher Scientific) and quantified by real-time quantitative PCR using commercially available primer/probes sets (Assay-On-Demand, Thermo Fisher Scientific): *GAPDH* (Hs99999905_m1) and *IRF7* (Hs01014809_g1). Real-time PCR was performed on a 7500 Fast Dx Real-Time PCR Instrument (Thermo Fisher Scientific). Relative expressions for the mRNA transcripts were calculated using the ΔΔC~t~ method and *GAPDH* mRNA transcript as reference.

2.8. Phenotype evaluation {#sec2.8}
-------------------------

After 24 h of culture, pDCs were harvested and stained with FVD eFluor™ 506, treated with human Fc block (Miltenyi Biotec) and stained with the following antibodies: AA750-CD80, PC5.5-CD86, FITC-HLA-DR (Beckman Coulter), PE-CCR7 (Thermo Fisher Scientific), APC-programmed cell death-ligand 1 (PD-L1, BD Biosciences) or the corresponding isotype controls. The relative fluorescence intensity (RFI) ratios were calculated by normalizing the RFI of the indicated to the condition of non-activated pDCs without As~2~O~3~ treatment.

2.9. Mixed lymphocyte reaction (MLR) {#sec2.9}
------------------------------------

For the pDC/CD4^+^ T cell coculture system, pDCs were cultured for 24 h with 0.25--0.5 μmol/L As~2~O~3~ in the presence of 10 ng/mL IL-3, simultaneously activated with CpG-A or CpG-B, and washed twice before co-culture. Allogeneic naïve CD4^+^ T cells were isolated from PBMC using MagniSort™ Human CD4 Naïve T cell Enrichment Kit (Thermo Fisher Scientific). After isolation, CD4^+^ T cells were labeled with Cell Proliferation Dye eFluor® 450 (Thermo Fisher Scientific) and co-cultured with pDCs at a 2:1 ratio for 7 days. T cell proliferation was assessed at day-5 of culture by flow cytometry. For intracellular cytokine detection, cells were harvested at day-7 of culture and stimulated for 5 h with 25 ng/mL phorbol-12-myristate-13-acetate (PMA, Sigma--Aldrich) and 1 μg/mL ionomycin (Sigma--Aldrich), and 1 μL/mL Golgi plug. Afterwards, cells were stained with FVD 575 V (BD Biosciences), followed by staining with PE/Dazzle 594-CD3 (Biolegend) and PC7-CD4 (BD Biosciences). Finally, cells were stained with PE-IFN-*γ*, APC-Vio770-TNF-*α*, eFluor660-IL-22 (Thermo Fisher Scientific) and Vio-515-IL-10 (Miltenyi) with Cytofix/Cytoperm Buffer (BD Biosciences).

For the pDC/B cell co-culture system, pDCs were pre-treated for 24 h with 0.5 μmol/L As~2~O~3~ in the presence of 10 ng/mL IL-3, and washed twice before co-culture. Syngeneic CD19^+^ B cells were isolated from PBMC using MagniSort® Human CD19 Positive Selection Kit (Thermo Fisher Scientific), and co-cultured with pDCs at a 3:1 ratio, in the presence of 1 μmol/L CpG-P for 3 days. Cells were then stained with FITC-CD19, ECD-CD24, PC5.5-CD38 (all from Beckman Coulter), and BV421-CD27 (Biolegend).

2.10. ELISA {#sec2.10}
-----------

ELISA kits of IFN-*α* (Thermo Fisher Scientific), TNF-*α*, IL-6 (PeproTech, Neuilly-sur-Seine, France) and CXCL10 (Biolegend) were used to detect these cytokine/chemokine concentrations in supernatants of pDC cultures.

2.11. Flow cytometry {#sec2.11}
--------------------

Analyses were performed with CytoFLEX Flow Cytometer (Beckman Coulter) and Kaluza Flow Cytometry Analysis Software version 1.5a (Beckman Coulter).

2.12. Statistical analysis {#sec2.12}
--------------------------

The Student\'s *t*-test was used for comparison between conditions. All data were analyzed using GraphPad Prism 5.0 (GraphPad Software, San Diego, CA, USA). A *P* \< 0.05 was considered to be significant.

3. Results {#sec3}
==========

3.1. High concentrations of As~2~O~3~ induces pDC apoptosis via mitochondrial pathway with BAX/BCL-2 ratio increase {#sec3.1}
-------------------------------------------------------------------------------------------------------------------

In the treatment of APL, patients' plasma As~2~O~3~ reaches the peak level of around 6 μmol/L about 3--4 h after administration and quickly decreases to a stable concentration between 0.5 and 3 μmol/L[@bib19]. Therefore, concentrations up to 2 μmol/L were considered as clinical relevant. We cultured pDCs purified from healthy donors in the presence of different doses of As~2~O~3~ for 6 or 24 h, respectively. After 6 h of treatment, up to 2 μmol/L of As~2~O~3~ induced neither significant increase of pDC apoptosis ([Fig. 1](#fig1){ref-type="fig"}A and B) nor decrease of viable pDCs ([Fig. 1](#fig1){ref-type="fig"}A and C). Five μmol/L of As~2~O~3~, however, significantly increased pDC apoptosis ([Fig. 1](#fig1){ref-type="fig"}A and B) and decreased the pDC viability ([Fig. 1](#fig1){ref-type="fig"}A and C). Meanwhile, there was a significantly lower degree of apoptosis in the CpG-A activated group as compared with the non-activated group, revealing a protective nature of CpG-A activation against apoptosis induction ([Fig. 1](#fig1){ref-type="fig"}B). After 24 h, there was an As~2~O~3~ dose-dependent decrease of viable pDC percentages, with concentrations equal or over 1 μmol/L significantly decreased viability of both non-activated and CpG-A activated pDCs. The CpG-P activated pDCs were more resistant to As~2~O~3~, whose viability significantly decreased with equal or over 2 μmol/L ([Fig. 1](#fig1){ref-type="fig"}D). Moreover, for all the concentrations investigated, percentages of apoptotic pDCs were below 5% after 24 h culture, probably due to the death of apoptotic cells between 6 and 24 h (data not shown). Accordingly, we used higher concentration (5 μmol/L) of As~2~O~3~ for pDC apoptotic tests, and non-toxic concentrations of As~2~O~3~ for all the following functional tests on pDCs.Figure 1As~2~O~3~ induces pDC apoptosis *via* mitochondrial pathway with BAX/BCL-2 ratio increase. Purified pDCs were cultured with indicated doses of As~2~O~3~ before tests. (A) Representative graph of pDC apoptosis after 6 h of culture \[*n* = 4 independent healthy donors (HD)\]. Percent of (B) apoptotic or (C) viable cells after 6 h culture with 0--5 μmol/L As~2~O~3~ (*n* = 4 HD). (D) Percent of viable cells after 24 h culture (*n* = 4 HD) (E) Percent of BAX^+^ cells (*n* = 4 HD), MFI of BAX (*n* = 4 HD), (F) MFI of BCL-2 (*n* = 4 HD), and (G) BAX/BCL-2 MFI ratio (*n* = 4 HD) after 6 h culture with 5 μmol/L As~2~O~3~. (H) Representative graph of intracellular ROS with (black) or without (grey) 5 μmol/L As~2~O~3~ for 30 min (*n* = 5 HD). (I) MFI of the ROS (*n* = 5 HD). Data are represented as mean ± SEM. \**P* \< 0.05, ^\*\*^*P* \< 0.01 and ^\*\*\*^*P* \< 0.001 by *t*-test.Figure 1

BAX and BCL-2 are key members of the BCL-2 family proteins within the mitochondrial apoptotic pathway, and the BAX to BCL-2 ratio determines cell survival/death following an apoptotic stimulus[@bib20]. We observed that BAX was greatly upregulated, while BCL-2 was slightly decreased in pDCs treated with 5 μmol/L of As~2~O~3~ for 6 h ([Fig. 1](#fig1){ref-type="fig"}E and F and Supporting Information [Fig. S1](#appsec3){ref-type="sec"}), leading to a significantly increased BAX/BCL-2 ratio ([Fig. 1](#fig1){ref-type="fig"}G). As~2~O~3~ is a well-known inducer of oxidative stress, an initiator of apoptosis. However, we observed that although 5 μmol/L of As~2~O~3~ increased the intracellular ROS in non-activated pDCs ([Fig. 1](#fig1){ref-type="fig"}H and I), the anti-oxidant NAC pre-treatment, which significantly reduced the intracellular ROS level (Supporting Information [Figs. S2A and B](#appsec3){ref-type="sec"}) without affecting pDCs viability ([Figs. S2C and D](#appsec3){ref-type="sec"}), did not prevent the As~2~O~3~-induced pDC apoptosis ([Fig. S2E](#appsec3){ref-type="sec"}).

3.2. Clinical-relevant As~2~O~3~ inhibits cytokine secretion of pDCs, with special potency on IFN-α {#sec3.2}
---------------------------------------------------------------------------------------------------

PBMCs were incubated with CpG-A and up to 2 μmol/L As~2~O~3~ for 6 h, which induced neither pDC death nor apoptosis, and IFN-*α*/TNF-*α* secretions were analyzed by intracellular staining on gated viable pDCs (Supporting Information [Figs. S3A and B](#appsec3){ref-type="sec"}). Surprisingly, we observed that As~2~O~3~ significantly inhibited the production of IFN-*α* dose-dependently, but not TNF-*α*, for either percentages of cytokine secretion cells ([Fig. 2](#fig2){ref-type="fig"}A) or the mean florescent intensity (MFI) of cytokine expressions of all gated viable pDCs (Supporting Information [Figs. S4A and B](#appsec3){ref-type="sec"}). However, ELISA analysis of supernatants of purified pDCs after 24 h culture showed that non-lethal As~2~O~3~ inhibited secretion of both IFN-*α* and TNF-*α* significantly ([Fig. 2](#fig2){ref-type="fig"}B). Moreover, IL-6 and CXCL10 productions were also slightly decreased but not statistically significant (Supporting Information [Fig. S5](#appsec3){ref-type="sec"}).Figure 2As~2~O~3~ preferentially blocks IFN-*α* production from pDCs *via* IRF7 inhibition. (A) Percent of IFN-*α*/TNF-*α* positive viable pDCs after PBMC incubation with indicated doses of As~2~O~3~ for 6 h (*n* = 4 HD). (B) Concentrations of indicated cytokines in supernatants of purified pDCs for 24 h with As~2~O~3~, normalized to concentration per viable cell (*n* = 5 HD). For (C) to (G), purified pDCs were cultured with 1 μmol/L As~2~O~3~ overnight before tests, gated on living cells. (C) and (F) Representative graph of IRF7 and phospho-IRF7, after incubation with (dotted line) or without As~2~O~3~ (solid line), and the isotype control (grey) (*n* = 5 HD). (D) Percent of IRF7^+^ cells (*n* = 5 HD). (E) MFI of IRF7 (*n* = 5 HD). (G) Percent of IRF7^+^ cells (*n* = 5 HD). (H) *IRF7* mRNA expression within purified pDCs cultured with 1 μmol/L As~2~O~3~ for 6 h (*n* = 4 HD). Data are represented as mean ± SEM. \**P* \< 0.05, ^\*\*^*P* \< 0.01 and ^\*\*\*^*P* \< 0.001 by *t*-test.Figure 2

3.3. As~2~O~3~ blocks IFN-α secretion from pDCs via IRF7 inhibition {#sec3.3}
-------------------------------------------------------------------

Decrease of TNF-*α*, IL-6 and CXCL10 secretion from pDCs were probably due to As~2~O~3~ inhibition of the NF-*κ*B pathway[@bib4]^,^[@bib21]. However, the reason for the quick and potent inhibition of IFN-*α* remained to be elucidated. We focused on IRF7, a crucial and specific regulator of both the induction and maintenance of IFN-*α* secretion by pDCs[@bib22]. Overnight incubation with 1 μmol/L of As~2~O~3~ induced a significant decrease of both the percentage of IRF7^+^ pDCs and MFI of IRF7 from both non-activated and CpG-A activated pDCs, gated on viable pDCs ([Fig. 2](#fig2){ref-type="fig"}C--E). Meanwhile, the percentage of phospho-IRF7^+^ pDCs was also significantly decreased in both non-activated and CpG-A activated conditions ([Fig. 2](#fig2){ref-type="fig"}F and G). Further RT-PCR experiments demonstrated the inhibition on the mRNA level, in both non-activated and CpG-A activated conditions ([Fig. 2](#fig2){ref-type="fig"}H).

3.4. As~2~O~3~ induces regulatory phenotype of pDCs {#sec3.4}
---------------------------------------------------

It has been shown that As~2~O~3~ induced a suppressive phenotype on immature DCs[@bib23]. We addressed whether pDC maturation could also be influenced by As~2~O~3~ treatment. For this purpose, isolated pDCs were incubated with non-lethal doses of As~2~O~3~ for 24 h, simultaneously activated with CpG-A, and checked for the expression of maturation markers ([Fig. 3](#fig3){ref-type="fig"}A). The results showed that 0.5 μmol/L of As~2~O~3~ significantly decreased the RFI ratio of CD80, CD86, and HLA-DR, as well as the percentages of CD86^+^ and CCR7^+^ activated pDCs. We also observed an up-regulated expression of PD-L1 ([Fig. 3](#fig3){ref-type="fig"}B and C).Figure 3As~2~O~3~ induces regulatory phenotype of pDCs. Isolated pDCs were incubated with/without CpG-A activation, with indicated doses of As~2~O~3~ for 24 h before flow cytometry analysis. (A) Representative graph showing cells positive for the indicated surface molecule in the presence of 0.5 μmol/L As~2~O~3~ (dotted line), control (solid line) and the isotype control (grey) (*n* = 4 HD). (B) Relative fluorescence intensity (RFI) ratios of indicated surface molecules (*n* = 4 HD). (C) Percentages of positive cells for indicated surface molecule (*n* = 4 HD). Data are represented as mean ± SEM. \**P* \< 0.05, ^\*\*^*P* \< 0.01 by *t*-test.Figure 3

3.5. As~2~O~3~ impairs pDCs' capacity to induce CD4^+^ T cell proliferation and Th1/Th22 polarization {#sec3.5}
-----------------------------------------------------------------------------------------------------

We used a pDC/CD4^+^ T cell co-culture system to investigate As~2~O~3~' effects on pDCs' capacity to induce T cell proliferation and polarization. Flow cytometry analysis showed that when pDCs were pretreated with 0.5 μmol/L of As~2~O~3~ for 24 h, together with CpG-B activation, they induced significantly lower percentages of proliferating CD4^+^ T cells after 5 days of co-culture ([Fig. 4](#fig4){ref-type="fig"}A and B). We then investigated the effect of As~2~O~3~ treatment on the pDC capacity to polarize allogeneic naïve CD4^+^ T cells. Flow cytometry analysis showed that when naïve CD4^+^ T were co-cultured with activated pDCs pre-treated with As~2~O~3~, there was a significant decrease in the percentages of IFN-*γ* ([Fig. 4](#fig4){ref-type="fig"}C and D) and IL-22 ([Fig. 4](#fig4){ref-type="fig"}E and F) positive proliferating CD4^+^ T cells after 7 days. However, As~2~O~3~ did not alter the percentages of IL-10 or TNF-*α* positive proliferating CD4^+^ T cells significantly (Supporting Information [Fig. S6](#appsec3){ref-type="sec"}).Figure 4As~2~O~3~ impairs pDCs\' capacity to induce CD4^+^ T cell proliferation and Th1/Th22 polarization. A pDC/CD4^+^ cell co-culture system was used. T cell proliferation and polarization was detected on day-5 and day-7 of co-culture, respectively. (A) Representative graph of cell proliferation (*n* = 4). (B) CD4^+^ T cells negative for cell proliferation dye (*n* = 4). (C) Representative graph of IFN-*γ*^+^ and TNF-*α*^+^ proliferating T cells gated on cell proliferation dye-negative cells (*n* = 4). (D) Percent of IFN-*γ*^+^ proliferating T cells (*n* = 4). (E) Representative graph of IFN-*γ*^+^ and IL-22^+^ proliferating T cells gated on cell proliferation dye-negative cells (*n* = 4). (F) % of IL-22^+^ proliferating T cells (*n* = 4). Data are represented as mean ± SEM. \**P* \< 0.05, ^\*\*^*P* \< 0.01 by *t*-test.Figure 4

3.6. As~2~O~3~ inhibits plasmablast differentiation of B cells {#sec3.6}
--------------------------------------------------------------

We used a pDC/B cell co-culture model to investigate As~2~O~3~' effects on pDCs' capacity to induce B cell differentiation towards plasmablasts[@bib24]. The flow cytometry results showed that pDCs, together with CpG-P, induced CD27^hi^CD38^hi^ plasmablast differentiation of syngeneic B cells. When pDCs were pretreated with 0.5 μmol/L of As~2~O~3~ for 24 h, significantly lower percentages of plasmablasts were induced ([Fig. 5](#fig5){ref-type="fig"}A and B). Given that IFN-*α*/IL-6 secretion and cell-to-cell contacts mediate pDC-induced B cell differentiation, we subsequently observed that 24 h culture of as low as 0.25 μmol/L of As~2~O~3~ decreased greatly the IFN-*α* secretion from CpG-P activated pDCs, with IL-6 inhibition shown at a higher concentration ([Fig. 5](#fig5){ref-type="fig"}C). Meanwhile, As~2~O~3~ significantly decreased CD86^+^ pDCs, and increased PD-L1 expression on CpG-P activated pDCs ([Fig. 5](#fig5){ref-type="fig"}D), with the CD80, HLA-DR, and CCR7 expressions not significantly altered (Supporting Information [Fig. S7](#appsec3){ref-type="sec"}).Figure 5As~2~O~3~ reduces pDCs\' ability to induce plasmablast differentiation of B cells. A pDC/B cell co-culture model was used. CD38^hi^CD27^hi^ plasmablast differentiation was analyzed on day-3 of co-culture. (A) Representative graph of CD38^hi^CD27^hi^ plasmablasts, gated on CD19^+^ cells (*n* = 4). (B) Percent of CD38^hi^CD27^hi^ plasmablasts among all gated B cells (*n* = 4). For (C) to (D), isolated pDCs were incubated with/without CpG-P activation, with indicated doses of As~2~O~3~ for 24 h before analysis. (C) IFN-*α* and IL-6 concentrations in supernatants of purified pDCs (*n* = 4 HD). (D) RFI ratios and percentages of positive cells for CD86 and PD-L1 (*n* = 4 HD). Data are represented as mean ± SEM. \**P* \< 0.05, ^\*\*^*P* \< 0.01 by *t*-test.Figure 5

3.7. SSc pDCs are sensitive to As~2~O~3-~induced selective IFN-α inhibition, and regulatory phenotype {#sec3.7}
-----------------------------------------------------------------------------------------------------

In order to further investigate As~2~O~3~ as a potential therapeutic agent for SSc, we first tested As~2~O~3~ on PBMCs from 12 untreated SSc patients. After incubation with CpG-A and clinical relevant doses of As~2~O~3~ for 6 h, IFN-*α* production was inhibited dose-dependently, but not TNF-*α* from pDCs of SSc patients ([Fig. 6](#fig6){ref-type="fig"}A). We then checked how As~2~O~3~ affected the viability and phenotype of pDCs purified from 6 additional SSc patients (for all patients information, see Supporting Information [Table S1](#appsec3){ref-type="sec"}). After 24 h of culture, 0.5 μmol/L of As~2~O~3~, which is non-lethal for pDCs from healthy donors, significantly decreased, albeit not hugely, the viability of both non-activated and CpG-A activated SSc pDCs ([Fig. 6](#fig6){ref-type="fig"}B). An increased BAX/BCL-2 ratio was also observed when these cells were cultured for 6 h with high dose of 5 μmol/L As~2~O~3~ ([Fig. 6](#fig6){ref-type="fig"}C--E). For phenotype, 24 h culture with 0.5 μmol/L of As~2~O~3~ decreased significantly both the MFI and the percentages of CD80^+^ and CD86^+^ SSc pDCs, while increased both the MFI and the percentage of PD-L1^+^ SSc pDCs, with CCR7 and HLA-DR expressions unchanged ([Fig. 6](#fig6){ref-type="fig"}F and G).Figure 6As~2~O~3~-induced pro-apoptotic effects, selective IFN-α inhibition, and regulatory phenotype are not resistant by SSc pDCs. (A) Percent of IFN-*α* and TNF-*α* positive pDCs after PBMCs from SSc patients were incubated with indicated doses of As~2~O~3~ for 6 h \[*n* = 12 SSc patients (SP)\]. For (B) to (G), purified SSc pDCs were cultured with indicated doses of As~2~O~3~ before tests. (B) Percent of viable SSc pDCs after 24 h (*n* = 5 SP). (C) Percent of BAX^+^ cells, and MFI of BAX expression in all pDCs, after 6 h (*n* = 3 SP). (D) MFI of BCL-2 in all pDCs after 6 h (*n* = 3 SP). (E) BAX/BCL-2 MFI ratio after 6 h (*n* = 3 SP). (F) RFI ratios and (G) Percent of positive cells for indicated surface molecules, after 24 h (*n* = 5 SP). Data are represented as mean ± SEM. \**P* \< 0.05, ^\*\*^*P* \< 0.01 and ^\*\*\*^*P* \< 0.001 by *t*-test.Figure 6

4. Discussion {#sec4}
=============

With this study, we concluded that in clinical conditions, As~2~O~3~ may induce pDC apoptosis during the first hours of drug administration. Afterwards, clinical relevant concentrations of As~2~O~3~ do not alter viability, but induce mostly functional alterations of pDCs. The survival of the resting state pDCs depend predominantly on the mitochondrial BCL-2 pathway, while the survival of activated pDCs is regulated by several pathways[@bib25]^,^[@bib26]. The pro-apoptotic protein BAX and the anti-apoptotic protein BCL-2 are important players in the mitochondrial apoptotic pathway[@bib27], and the BAX/BCL-2 ratio determines survival or death following an apoptotic stimulus[@bib20]. We found that As~2~O~3~ induced a significantly increased BAX/BCL-2 ratio in pDCs. Moreover, antioxidant NAC did not reverse As~2~O~3~-induced pDC apoptosis. Collectively, As~2~O~3~ induced pDC apoptosis *via* the mitochondrial pathway with increased BAX/BCL-2 ratio, and independent of ROS generation.

We observed that As~2~O~3~ inhibited pDC secretion of IFN-*α*, which may consequently impair the pDCs' capacity to promote effector CD8^+^ and Th1 cell responses, to drive B cell activation and plasma cell generation[@bib28]. Meanwhile, the observed inhibition of TNF-*α*, IL-6 and CXCL10 could reduce capacity of pDCs to upregulate inflammatory reactions and to attract immune cells to sites of infection or inflammation[@bib21].

A 'cross-regulation' effect between IFN-I and TNF-*α* was previously described in pDCs where TNF-*α* blockade decreased pDC maturation and promoted their ability to produce IFN-I, leading to possible novel autoimmune side-effects[@bib29]^,^[@bib30]. In our study, As~2~O~3~ inhibited both IFN-*α* and TNF-*α* secretion, as well as maturation of pDCs. These effects were probably due to 'double-target' effects of As~2~O~3~ on both IRF7 and the NF-*κ*B pathways[@bib4]^,^[@bib21]. Moreover, the IRF7 pathway seems to be much more sensitive to As~2~O~3~, as compared to the NF-*κ*B pathway. We observed that clinical relevant concentrations of As~2~O~3~, which induced neither pDC death nor apoptosis, potently inhibited IFN-*α*, while leaving TNF-*α* unchanged at 6 h of culture. Meanwhile, IRF7 expression and phosphorylation were potently inhibited[@bib28]^,^[@bib31]. Indeed, the IFN-I secretion by pDCs is predominantly (albeit not exclusively) mediated through the myeloid differentiation primary response protein 88 (MYD88)-IRF7 pathway[@bib32]. Especially, for the TLR9 ligands CpG ODNs used to activate pDCs in this study, the IFN-I secretion by pDCs seems to be solely mediated through MYD88-IRF7 signaling[@bib33]. We speculate that the IRF7 protein may contain a special domain, offering itself high affinity for soluble trivalent arsenic[@bib34]. Moreover, in pDCs, MYD88-IRF7 is the downstream signaling of TLR-mediated and other cytosolic receptor-mediated nucleic acid sensing. The diminished phosphorylation of IRF7 indicates a probable effect of As~2~O~3~ on pDC nucleic sensing[@bib35].

Upon TLR7 or TLR9 mediated activation, pDCs mature and express MHC class I (MHCI) and class II (MHCII) molecules and co-stimulatory markers, which operate together to cross-prime CD8^+^ T cells and present antigen to CD4^+^ T cells[@bib21]. Mature pDCs also express co-inhibitory molecules such as PD-L1[@bib36]^,^[@bib37], and induce regulatory T cell responses[@bib28]. In this study, As~2~O~3~ inhibited expression of co-stimulatory molecules and chemokine receptors, indicating that it impaired pDCs' trafficking and antigen-presenting capacity.

In line with these observations, we showed that As~2~O~3~ treatment significantly impaired activated pDCs to promote CD4^+^ T cell proliferation and Th1/Th22 polarizations. The preferential inhibition of type-I IFN secreted by pDCs after As~2~O~3~ treatment probably contributed to the deficiency of Th1 pro-inflammatory response[@bib38]. Since abnormal T cell proliferation plays an important role in the pathogenesis of SSc[@bib2]^,^[@bib10], and both Th1 and Th22 immune responses are involved in the development of SSc[@bib39]^,^[@bib40], these observations highlight an important role of As~2~O~3~ in modulating T cell responses in SSc. Nevertheless, pDCs regulate B cell growth and differentiation *via* both cytokine secretion and cell-to-cell contact[@bib16], [@bib17], [@bib18]. Altered B cell homeostasis characterized by hyperactivity of plasmablasts and autoantibodies production are reported in patients with SSc[@bib41]. We observed in this study that As~2~O~3~ potently impaired the pDC ability to induce B cell differentiation towards plasmablasts, revealing another important role of As~2~O~3~ in B cell regulation in SSc.

Regarding effects of As~2~O~3~ on other immune subsets, previous studies have shown that T and B cells\' viability were not significantly affected by clinical relevant concentrations of As~2~O~3~[@bib42]^,^[@bib43]. In addition, As~2~O~3~ have been reported not to alter viability, but to repress the monocyte-derived dendritic cells' capacity to induce Th1 and Th17 responses[@bib23]. Therefore, both conventional DCs and pDCs probably contribute to As~2~O~3~ induced immunomodulation *in vivo*. Moreover, it was reported that pDC functions were influenced by a microenvironment enriched in apoptotic cells, leading to Treg increase[@bib44]. Therefore, since clinical relevant concentrations of As~2~O~3~ induce significant apoptosis of monocytes[@bib45], these apoptotic cells may facilitate As~2~O~3~-induced pDC immunomodulation *in vivo*.

Chronically activated pDCs are responsible for most of the IFN-*α* secretion in SSc patients, and play a critical role during the process of fibrosis[@bib7]^,^[@bib46]. We observed that similar to healthy pDCs, As~2~O~3~ induced preferential inhibition of IFN-*α* secretion, pro-apoptotic effects, and regulatory phenotype in SSc pDCs, indicating that As~2~O~3~ effects on pDCs from SSc patients were uncompromised.

5. Conclusions {#sec5}
==============

Overall, we have described the pharmacological effects and mechanisms of As~2~O~3~ on pDCs, which offer an important theoretical explanation for the efficacy of As~2~O~3~ on SSc, and may pave the way to As~2~O~3~ utilization in more autoimmune diseases with type-I IFN signature.
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